Proqr Therapeutics Bv Stock Current Valuation
| PRQR Stock | USD 3.62 0.01 0.28% |
Valuation analysis of ProQR Therapeutics helps investors to measure ProQR Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 11/22/2024, Enterprise Value Over EBITDA is likely to drop to -2. In addition to that, Enterprise Value Multiple is likely to drop to -2. Fundamental drivers impacting ProQR Therapeutics' valuation include:
Price Book 14.5122 | Enterprise Value 306.4 M | Enterprise Value Ebitda (2.10) | Price Sales 20.7943 | Enterprise Value Revenue 16.2476 |
Overvalued
Today
Please note that ProQR Therapeutics' price fluctuation is extremely dangerous at this time. Calculation of the real value of ProQR Therapeutics is based on 3 months time horizon. Increasing ProQR Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ProQR stock is determined by what a typical buyer is willing to pay for full or partial control of ProQR Therapeutics BV. Since ProQR Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ProQR Stock. However, ProQR Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.62 | Real 2.81 | Target 3.93 | Hype 3.61 | Naive 3.82 |
The intrinsic value of ProQR Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ProQR Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ProQR Therapeutics BV helps investors to forecast how ProQR stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ProQR Therapeutics more accurately as focusing exclusively on ProQR Therapeutics' fundamentals will not take into account other important factors: ProQR Therapeutics BV Company Current Valuation Analysis
ProQR Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ProQR Therapeutics Current Valuation | 306.39 M |
Most of ProQR Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ProQR Therapeutics BV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ProQR Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for ProQR Therapeutics is extremely important. It helps to project a fair market value of ProQR Stock properly, considering its historical fundamentals such as Current Valuation. Since ProQR Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ProQR Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ProQR Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
ProQR Current Valuation Historical Pattern
Today, most investors in ProQR Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ProQR Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ProQR Therapeutics current valuation as a starting point in their analysis.
ProQR Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ProQR Therapeutics BV has a Current Valuation of 306.39 M. This is 97.87% lower than that of the Biotechnology sector and 93.4% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.16% higher than that of the company.
ProQR Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ProQR Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ProQR Therapeutics could also be used in its relative valuation, which is a method of valuing ProQR Therapeutics by comparing valuation metrics of similar companies.ProQR Therapeutics is currently under evaluation in current valuation category among its peers.
ProQR Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ProQR Therapeutics from analyzing ProQR Therapeutics' financial statements. These drivers represent accounts that assess ProQR Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ProQR Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 362.6M | 172.0M | 452.1M | 247.6M | 145.1M | 192.7M | |
| Enterprise Value | 264.2M | 130.5M | 324.9M | 174.7M | 45.9M | 43.6M |
ProQR Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ProQR Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ProQR Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
ProQR Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.30) % | ||||
| Operating Margin | (2.19) % | ||||
| Current Valuation | 306.39 M | ||||
| Shares Outstanding | 105.91 M | ||||
| Shares Owned By Insiders | 14.49 % | ||||
| Shares Owned By Institutions | 24.90 % | ||||
| Number Of Shares Shorted | 677.63 K | ||||
| Price To Earning | (1.97) X | ||||
| Price To Book | 14.51 X | ||||
| Price To Sales | 20.79 X | ||||
| Revenue | 6.51 M | ||||
| Gross Profit | 4.8 M | ||||
| EBITDA | (24.1 M) | ||||
| Net Income | (27.54 M) | ||||
| Cash And Equivalents | 156.4 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 19.73 M | ||||
| Debt To Equity | 0.70 % | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | 21.55 M | ||||
| Short Ratio | 0.21 X | ||||
| Earnings Per Share | (0.32) X | ||||
| Target Price | 7.03 | ||||
| Number Of Employees | 156 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 382.32 M | ||||
| Total Asset | 138 M | ||||
| Retained Earnings | (400.85 M) | ||||
| Working Capital | 86.78 M | ||||
| Current Asset | 97.77 M | ||||
| Current Liabilities | 5.49 M | ||||
| Net Asset | 138 M |
About ProQR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProQR Therapeutics BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProQR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProQR Therapeutics BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ProQR Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against ProQR Stock
| 0.84 | ME | 23Andme Holding | PairCorr |
| 0.84 | MTEM | Molecular Templates | PairCorr |
| 0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.79 | TPST | Tempest Therapeutics | PairCorr |
| 0.76 | AGL | agilon health | PairCorr |
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.